By contrast, numerous studies have shown that intestine-specific FXR-deficiency and pharmacological inhibition of intestinal FXR protect mice from HFD-induced obesity, insulin resistance and NAFLD21–24, these beneficial effects being mediated, at least in part, via decreased intestinal ceramide synthesis and secretion41. The gene discussed is NR1H4; the disease is obesity disorder.